Orchard Therapeutics’ (NASDAQ:ORTX) lock-up period will end on Monday, April 29th. Orchard Therapeutics had issued 14,285,715 shares in its IPO on October 31st. The total size of the offering was $200,000,010 based on an initial share price of $14.00. After the expiration of Orchard Therapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research cut shares of Orchard Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 2nd. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of Orchard Therapeutics in a report on Friday, March 22nd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Orchard Therapeutics presently has a consensus rating of “Buy” and an average price target of $23.40.

NASDAQ:ORTX opened at $17.79 on Monday. Orchard Therapeutics has a 52 week low of $8.65 and a 52 week high of $21.64. The company has a market cap of $1.53 billion and a PE ratio of -1.74.

Institutional investors have recently modified their holdings of the stock. Dean Capital Investments Management LLC bought a new position in Orchard Therapeutics during the fourth quarter valued at approximately $674,000. Baillie Gifford & Co. bought a new position in Orchard Therapeutics during the fourth quarter valued at approximately $14,550,000. RA Capital Management LLC bought a new position in Orchard Therapeutics during the fourth quarter valued at approximately $76,227,000. Temasek Holdings Private Ltd bought a new position in Orchard Therapeutics during the fourth quarter valued at approximately $15,730,000. Finally, Victory Capital Management Inc. bought a new position in Orchard Therapeutics during the fourth quarter valued at approximately $106,000. Institutional investors own 56.65% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Orchard Therapeutics PLC -‘s Lock-Up Period Set To End on April 29th (NASDAQ:ORTX)” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/orchard-therapeutics-plc-s-lock-up-period-set-to-end-on-april-29th-nasdaqortx/2979999.html.

Orchard Therapeutics Company Profile

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Recommended Story: How dollar cost averaging works

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.